Reig Jofre Reaches 15 Million Units Sold of its Anesthetic in Japan

Reig Jofre, a Catalan pharmaceutical company has announced the marketing in Japan of fifteen million vials of the anesthetic remifentanil together with its partner Maruishi Pharmaceutical, an intravenous solution for hospital use. The plants that the company has in Barcelona are responsible for 30% of the global supply of this product, developed internally by the company.

The company has assured that internationalization is one of the fundamental strategic pillars in the expansion of Reig Jofre. Beyond its arrival in Japan in 2016, the company has confirmed that it continues to grow in the Philippines, Indonesia, South Korea, and Myanmar, maintaining the Asian continent as one of its key strategic geographic areas.

Ignasi Biosca, CEO of Reig Jofre, has assured regarding the results in Japan that “we celebrate with great satisfaction this success, which has been possible thanks to the exceptional relationship forged and strengthened with Maruishi Pharmaceutical for more than a decade.” The manager added that “since our first contacts in 2013, we have built this relationship on the pillars of trust, transparent communication, and deep alignment of objectives.”

If you want to find more details about Reig Jofre and read the latest business news of the day, download for free our companion app Born2Invest.

55% of Reig Jofre turnover achieved in the third quarter has been related to international markets

Reig Jofre has announced that it intends to continue supplying this anesthetic in Japan for the next few years, as it is “the second largest pharmaceutical market in the world and has opened the door to the creation of new business opportunities .” In this way, the firm has declared that it will be able to expand its range of products from the Pharmaceutical Technologies unit.

This week the Catalan pharmaceutical company announced an annual growth of 22% in its income until the third quarter of 2023, which amounted to €237 million. Reig Jofre has assured that these results are a consequence of the development of the Specialty Pharmacare division and the greater utilization of the capacity of the new Barcelona plant.

In fact, 55% of the turnover achieved in the third quarter has been related to international markets, both from the company’s own subsidiaries around the world and from distribution and licensing agreements. Thanks to this international expansion, by the end of the year the company expects to reach €300 million in revenue.

Reig Jofre is a Spanish pharmaceutical laboratory founded in 1929. The company specializes in technological specialty products, therapeutic specialty products in the areas of dermatology, gynecology, and respiratory, as well as consumer healthcare products.

__

(Featured image by TheShiv76 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.